D. Atanackovic

G. Fasola, D. Atanackovic, J. Vansteenkiste, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer

D. Atanackovic, Michael Thomas, S. Koch, 2019, Cancer Immunology, Immunotherapy.

Ocular adverse events associated with chimeric antigen receptor T-cell therapy: a case series and review

D. Atanackovic, A. Rapoport, S. Dahiya, 2022, British Journal of Ophthalmology.

Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell–depleted lymphoma after CART therapy

T. Luetkens, D. Atanackovic, J. Baddley, 2022, Blood.

Humoral immunity against SARS‐CoV‐2 variants including omicron in solid organ transplant recipients after three doses of a COVID‐19 mRNA vaccine

T. Luetkens, D. Atanackovic, J. Baddley, 2022, Clinical & translational immunology.

Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy

T. Luetkens, D. Atanackovic, J. Baddley, 2021, Blood Advances.

Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).

J. Milanowski, C. Gridelli, D. Atanackovic, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting

C. Bokemeyer, Y. Hildebrandt, T. Luetkens, 2013, Human vaccines & immunotherapeutics.

accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation

C. Bokemeyer, J. Panse, T. Luetkens, 2008 .

NY‐CO‐58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer

C. Bokemeyer, K. Friedrichs, A. Marx, 2010, International journal of cancer.

A Th1/IFNg Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non–Small Cell Lung Cancer

J. Goeman, H. V. Houwelingen, J. Kirkwood, 2020 .

Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia.

C. Bokemeyer, T. Brümmendorf, Y. Hildebrandt, 2010, Leukemia research.

Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation

N. Kröger, D. Atanackovic, A. Zander, 2008, Haematologica.

Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study - AIO SUP-0108.

T. Luetkens, D. Atanackovic, J. Rüssel, 2016, European journal of cancer.

Expression of cancer-testis antigens as possible targets for antigen-specific immunotherapy in head and neck squamous cell carcinoma

C. Bokemeyer, K. Bartels, S. Wenzel, 2006, Cancer biology & therapy.

Is there any relationship between gene expression of tumor antigens and CD4+ T cells in multiple myeloma?

D. Atanackovic, G. Colleoni, W. M. Braga, 2014, Immunotherapy.

FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4+ T regulatory cells

D. Atanackovic, A. D. de Carvalho, E. Rizzatti, 2014, Cancer Immunology, Immunotherapy.

Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation.

C. Bokemeyer, K. Bartels, N. Kröger, 2007, Blood.

Effects of whole body hyperthermia (41.8 degrees C) on the frequency of tumor cells in the peripheral blood of patients with advanced malignancies.

D. Atanackovic, K. Pantel, D. Hossfeld, 2003, Clinical Cancer Research.

An optimized assay for the enumeration of antigen-specific memory B cells in different compartments of the human body.

C. Bokemeyer, Y. Hildebrandt, T. Luetkens, 2010, Journal of immunological methods.

Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers.

G. Sauter, C. Bokemeyer, A. Marx, 2010, Human pathology.

Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.

N. Kröger, D. Atanackovic, A. Zander, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma

T. Luetkens, K. Bartels, N. Kröger, 2015, Journal of Translational Medicine.

Acute effects of exercise on the inflammatory state in patients with idiopathic pulmonary arterial hypertension

C. Bokemeyer, L. Harbaum, D. Atanackovic, 2016, BMC Pulmonary Medicine.

Acute psychological stress induces a prolonged suppression of the production of reactive oxygen species by phagocytes

D. Atanackovic, H. Deter, M. Brunner‐Weinzierl, 2003, Journal of Neuroimmunology.

Oscillating expression of interleukin-16 in multiple myeloma is associated with proliferation, clonogenic growth, and PI3K/NFKB/MAPK activation

T. Luetkens, D. Atanackovic, Daniel Hasche, 2017, Oncotarget.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

C. Hofmeister, A. Krishnan, S. Singhal, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses

Yao-Tseng Chen, D. Atanackovic, N. Altorki, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Vaccine-Induced CD4+ T Cell Responses to MAGE-3 Protein in Lung Cancer Patients1

Yao-Tseng Chen, D. Atanackovic, N. Altorki, 2004, The Journal of Immunology.

A Th1/IFN g Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non – Small Cell Lung Cancer A

J. Goeman, H. V. Houwelingen, J. Kirkwood, 2020 .

HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones.

D. Jäger, Yao-Tseng Chen, J. Karbach, 2004, Cancer immunity.

HLA-DP 4 expression and immunity to NY-ESO-1 : correlation and characterization of cytotoxic CD 4 + CD 25-CD 8-T cell clones

D. Jäger, Yao-Tseng Chen, J. Karbach, 2004 .

Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC.

D. Atanackovic, L. Old, S. Gnjatic, 2003, Journal of immunological methods.

Physiology and Pharmacology of Temperature Regulation Patients with solid tumors treated with high-temperature whole body hyperthermia show a redistribution of naive / memory T-cell subtypes

D. Atanackovic, K. Braumann, D. Hossfeld, 2006 .

Peripheral T cells of patients with B cell non-Hodgkin's lymphoma show a shift in their memory status.

J. Panse, K. Bartels, D. Atanackovic, 2005, Leukemia research.

Characterization of Effusion-Infiltrating T Cells

D. Atanackovic, D. Hossfeld, A. de Weerth, 2004, Clinical Cancer Research.

T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccine

T. Luetkens, D. Atanackovic, J. Baddley, 2022, Journal for ImmunoTherapy of Cancer.

Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma.

G. Sauter, C. Bokemeyer, A. Marx, 2010, Experimental and molecular pathology.

MAGE-A3 cancer immunotherapeutic in resected stage IB-III NSCLC patients with or without sequential or concurrent chemotherapy.

G. Fasola, D. Atanackovic, J. Vansteenkiste, 2012 .

Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity

L. Harbaum, A. Marx, D. Atanackovic, 2013, International Journal of Hematology.

The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients.

C. Bokemeyer, Y. Hildebrandt, T. Luetkens, 2010, Experimental hematology.

Pleural effusion of a second neoplasm in a patient with B‐CLL: Two immunological compartments

D. Atanackovic, S. Hegewisch‐Becker, S. Brettner, 2003, American journal of hematology.

IFN-gamma enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation.

Yao-Tseng Chen, D. Atanackovic, I. Mellman, 2004, Proceedings of the National Academy of Sciences of the United States of America.

MAGE-3 Protein in Lung Cancer Patients Vaccine-Induced CD4+ T Cell Responses to

Yao-Tseng Chen, D. Atanackovic, N. Altorki, 2013 .

MAGE-3 Protein in Lung Cancer Patients T Cell Responses to + Vaccine-Induced CD4

Yao-Tseng Chen, D. Atanackovic, N. Altorki, 2004 .

Cross-Presentation of HLA Class I Epitopes from Exogenous NY-ESO-1 Polypeptides by Nonprofessional APCs 1

Yao-Tseng Chen, D. Atanackovic, L. Old, 2003, The Journal of Immunology.

Nonprofessional APCs from Exogenous NY-ESO-1 Polypeptides by Cross-Presentation of HLA Class I Epitopes

Yao-Tseng Chen, D. Atanackovic, D. Valmori, 2003 .

Pooled study of occupational exposure to aromatic hydrocarbon solvents and risk of multiple myeloma

N. Camp, J. Spinelli, S. de Sanjosé, 2018, Occupational and Environmental Medicine.

41.8°C whole body hyperthermia as an adjunct to chemotherapy induces prolonged T cell activation in patients with various malignant diseases

D. Atanackovic, D. Hossfeld, A. Nierhaus, 2002, Cancer Immunology, Immunotherapy.

A Pooled Analysis of Reproductive Factors, Exogenous Hormone Use, and Risk of Multiple Myeloma among Women in the International Multiple Myeloma Consortium

N. Camp, P. Brennan, S. de Sanjosé, 2015, Cancer Epidemiology, Biomarkers & Prevention.

Immunophenotypic and cytogenetic evolution patterns of the neoplastic plasma cells in multiple myeloma relapsed after stem cell transplant

D. Atanackovic, M. Salama, J. Hussong, 2018, Journal of Hematopathology.

The Role of Regulatory T Cells and TH17 Cells in Multiple Myeloma

D. Atanackovic, G. Colleoni, W. Braga, 2012, Clinical & developmental immunology.

Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells

Y. Hildebrandt, N. Kröger, D. Atanackovic, 2010, Bone Marrow Transplantation.

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

C. Hofmeister, S. Singhal, Rashmi Kumar, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status.

N. Kröger, D. Atanackovic, A. Zander, 2006, Experimental hematology.

Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma.

N. Kröger, D. Atanackovic, A. Zander, 2009, Experimental hematology.

Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study.

D. Atanackovic, U. Pichlmeier, D. Hossfeld, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Role of immunotherapy in Ewing sarcoma

T. Luetkens, D. Atanackovic, Michael L. Olson, 2020, Journal for ImmunoTherapy of Cancer.

The promise of adoptive cellular immunotherapies in hepatocellular carcinoma

T. Luetkens, D. Atanackovic, Michael L. Olson, 2019, Oncoimmunology.

B cell maturation antigen‐specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta‐analysis

N. Kröger, D. Atanackovic, F. Ayuk, 2019, European journal of haematology.

Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites?

C. Bokemeyer, D. Atanackovic, K. Oechsle, 2009, The oncologist.

Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma

C. Bokemeyer, J. Panse, A. Marx, 2011, Haematologica.

Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma.

M. Daly, N. Camp, Haiyuan Yu, 2018, Cancer research.

CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation

C. Bokemeyer, J. Panse, T. Luetkens, 2008, Haematologica.

Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

C. Hofmeister, A. Krishnan, S. Singhal, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Second autologous transplant as salvage therapy in multiple myeloma

D. Atanackovic, G. Schilling, 2013, British journal of haematology.

Immune-modulating drugs and hypomethylating agents to prevent or treat relapse after allogeneic stem cell transplantation.

N. Kröger, D. Atanackovic, T. Stübig, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Targeting MAGE-C1/CT7 Expression Increases Cell Sensitivity to the Proteasome Inhibitor Bortezomib in Multiple Myeloma Cell Lines

A. Camargo, D. Atanackovic, B. Strauss, 2011, PloS one.

An Anti-Programmed Death-1 Antibody (αPD-1) Fusion Protein That Self-Assembles into a Multivalent and Functional αPD-1 Nanoparticle.

D. Atanackovic, H. Yagita, S. Dong, 2017, Molecular pharmaceutics.

Booster vaccination of non-small cell lung cancer (NSCLC) patients with MAGEA3 protein and AS02B adjuvant

C. Bokemeyer, D. Atanackovic, N. Altorki, 2007 .

Targeting the tumor microenvironment of Ewing sarcoma.

T. Luetkens, D. Atanackovic, Michael L. Olson, 2021, Immunotherapy.

Biomarkers for checkpoint inhibition in hematologic malignancies.

T. Luetkens, D. Atanackovic, 2018, Seminars in cancer biology.

Chimeric Antigen Receptor (CAR) therapy for multiple myeloma

T. Luetkens, D. Atanackovic, S. Radhakrishnan, 2016, British journal of haematology.

A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors

D. Atanackovic, M. Friedrich, W. Fiedler, 2018, Oncoimmunology.

Autoantibodies against tumor-related antigens: incidence and biologic significance.

C. Bokemeyer, D. Atanackovic, S. Kobold, 2010, Human immunology.

Current standards and new trends in the primary treatment of colorectal cancer.

C. Bokemeyer, D. Atanackovic, A. Stein, 2011, European journal of cancer.

Fast off-rate CD229 chimeric antigen receptor T cells efficiently target multiple myeloma, spare T cells, and exhibit reduced trogocytosis

David P Ng, J. Panse, T. Luetkens, 2021 .

CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide

J. Panse, T. Luetkens, D. Atanackovic, 2020, Nature Communications.

Longitudinal Analysis of Tetanus- and Influenza-Specific IgG Antibodies in Myeloma Patients

C. Bokemeyer, Y. Hildebrandt, T. Luetkens, 2012, Clinical & developmental immunology.

Frequent intratumoral heterogeneity of EGFR gene copy gain in non-small cell lung cancer.

G. Sauter, C. Bokemeyer, D. Atanackovic, 2013, Lung cancer.

Characterization of different CTC subpopulations in non-small cell lung cancer

D. Atanackovic, K. Pantel, W. Knoefel, 2016, Scientific Reports.

Cancer‐testis antigen MAGEC2 promotes proliferation and resistance to apoptosis in Multiple Myeloma

Y. Hildebrandt, T. Luetkens, K. Bartels, 2015, British journal of haematology.

Outcomes of Busulfan, Fludarabine, and 400 cGy Total Body Irradiation Compared With Busulfan and Fludarabine Reduced-Intensity Conditioning Regimens for Allogeneic Stem Cell Transplantation in Adult Patients With Hematologic Diseases: A Single-Center Experience.

D. Atanackovic, A. Rapoport, S. Dahiya, 2023, Transplantation proceedings.

Immunotherapies targeting CD38 in Multiple Myeloma

T. Luetkens, D. Atanackovic, S. Radhakrishnan, 2016, Oncoimmunology.

A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci

J. Witte, M. Lieber, G. Colditz, 2016, Cancer Epidemiology, Biomarkers & Prevention.

Deep dissection of the antiviral immune profile of patients with COVID-19

T. Luetkens, D. Atanackovic, J. Baddley, 2021, Communications Biology.

Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation

C. Bokemeyer, A. Marx, Y. Hildebrandt, 2014, Cancer Immunology, Immunotherapy.

Effects of Whole Body Hyperthermia (41.8°C) on the Frequency of Tumor Cells in the Peripheral Blood of Patients with Advanced Malignancies

D. Atanackovic, K. Pantel, D. Hossfeld, 2003 .

Effects of Whole Body Hyperthermia ( 41 . 8 ° C ) on the Frequency of Tumor Cells in the Peripheral Blood of Patients with Advanced Malignancies 1

D. Atanackovic, K. Pantel, D. Hossfeld, 2003 .

Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion

T. Luetkens, D. Atanackovic, A. Welm, 2022, Leukemia.

Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk

H. Coon, N. Camp, C. Vachon, 2017, bioRxiv.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.

C. Hofmeister, S. Singhal, Rashmi Kumar, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022.

C. Hofmeister, S. Singhal, Rashmi Kumar, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Acute psychological stress alerts the adaptive immune response: Stress-induced mobilization of effector T cells

C. Bokemeyer, K. Bartels, D. Atanackovic, 2006, Journal of Neuroimmunology.

Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen‐A family and NY‐ESO‐1 cancer‐testis antigens represents an independent marker for poor survival in head and neck cancer

G. Sauter, T. Luetkens, D. Atanackovic, 2014, International journal of cancer.

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

R. Vij, D. Atanackovic, P. Moreau, 2021, Blood Cancer Journal.

Cancer-testis antigen MAGE-C2/CT10 induces spontaneous CD4+ and CD8+ T-cell responses in multiple myeloma patients

T. Luetkens, N. Kröger, D. Atanackovic, 2014, Blood Cancer Journal.

Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells

C. Bokemeyer, Y. Hildebrandt, T. Luetkens, 2010, Haematologica.

Longitudinal Analysis and Prognostic Effect of Cancer-Testis Antigen Expression in Multiple Myeloma

C. Bokemeyer, Y. Hildebrandt, T. Luetkens, 2009, Clinical Cancer Research.

Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung

G. Sauter, C. Bokemeyer, A. Marx, 2012, Modern Pathology.

CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients

Yao-Tseng Chen, D. Atanackovic, N. Altorki, 2002, Proceedings of the National Academy of Sciences of the United States of America.

A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer

C. Bokemeyer, D. Atanackovic, A. Stein, 2014, Gastric Cancer.

TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer

D. Atanackovic, B. Fehse, B Berdien, 2014, Gene Therapy.

A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non–Small Cell Lung Cancer

J. Goeman, H. V. van Houwelingen, J. Kirkwood, 2019, Clinical Cancer Research.

Decrease of CD4+FOXP3+ T regulatory cells in the peripheral blood of human subjects undergoing a mental stressor

C. Bokemeyer, Y. Hildebrandt, T. Luetkens, 2010, Psychoneuroendocrinology.

Prognostic and Diagnostic Value of Spontaneous Tumor-Related Antibodies

C. Bokemeyer, T. Luetkens, D. Atanackovic, 2010, Clinical & developmental immunology.

Chimeric Antigen Receptor (CAR) T Cells Specific for CD229: A Potentially Curative Approach for Multiple Myeloma

T. Luetkens, D. Atanackovic, D. Sborov, 2017 .

CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma

J. Panse, T. Luetkens, N. Kröger, 2015, Human vaccines & immunotherapeutics.

The impact of bridging therapy prior to CD19‐directed chimeric antigen receptor T‐cell therapy in patients with large B‐cell lymphoma

D. Atanackovic, Seung Tae Lee, A. Rapoport, 2021, British journal of haematology.

Immune parameters in patients with anxiety or depression during psychotherapy.

D. Atanackovic, S. Serke, H. Kröger, 2004, Journal of affective disorders.

Expression of Cancer-Testis Antigens MAGE-C1/CT7 and MAGE-A3 Is Central to the Survival of Myeloma Cells and Their Resistance to Chemotherapy

C. Bokemeyer, Y. Hildebrandt, T. Luetkens, 2008 .

Clinical Study Patients withMultiple Myeloma Develop SOX 2-Specific Autoantibodies after Allogeneic Stem Cell Transplantation

C. Bokemeyer, A. Marx, Y. Hildebrandt, 2014 .

Patients with Multiple Myeloma Develop SOX2-Specific Autoantibodies after Allogeneic Stem Cell Transplantation

C. Bokemeyer, A. Marx, Y. Hildebrandt, 2011, Clinical & developmental immunology.

Roadmap to affinity-tuned antibodies for enhanced chimeric antigen receptor T cell function and selectivity.

T. Luetkens, D. Atanackovic, Carol S. Lim, 2022, Trends in biotechnology.

Messenger RNA vaccination and B-cell responses in NSCLC patients.

D. Atanackovic, S. Koch, F. Mayer, 2012 .

Messenger RNA vaccination in NSCLC: Findings from a phase I/IIa clinical trial.

D. Atanackovic, R. Bals, F. Mayer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy

N. Kröger, D. Atanackovic, B. Fehse, 2013, Human vaccines & immunotherapeutics.

Acute psychological stress increases peripheral blood CD3+CD56+ natural killer T cells in healthy men: possible implications for the development and treatment of allergic and autoimmune disorders

C. Bokemeyer, Y. Hildebrandt, K. Bartels, 2013, Stress.

The role of surface molecule CD229 in Multiple Myeloma.

T. Luetkens, D. Atanackovic, Michael L. Olson, 2019, Clinical immunology.

Novel anti-myeloma immunotherapies targeting the SLAM family of receptors

T. Luetkens, D. Atanackovic, S. Radhakrishnan, 2017, Oncoimmunology.

In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab

T. Luetkens, N. Kröger, D. Atanackovic, 2019, Leukemia.

Genome-wide association study identiﬁes variants at 16p13 associated with survival in multiple myeloma patients

Jennifer L. Caswell-Jin, E. Ziv, N. Camp, 2022 .

Elotuzumab as a novel anti-myeloma immunotherapy

T. Luetkens, D. Atanackovic, S. Radhakrishnan, 2017, Human vaccines & immunotherapeutics.

Role of interleukin 16 in multiple myeloma.

C. Bokemeyer, J. Panse, A. Marx, 2012, Journal of the National Cancer Institute.

Successful transfer of anti–SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19

T. Luetkens, D. Atanackovic, A. Spivak, 2020, Blood Advances.

A local enrichment of regulatory T cells within the tumor tissue might suppress an effective anti-tumor T cell response in patients with head and neck cancer

K. Bartels, R. Leuwer, D. Atanackovic, 2005 .

Integrating patient reported measures as predictive parameters into decisionmaking about palliative chemotherapy: a pilot study

D. Atanackovic, A. Stein, K. Oechsle, 2016, BMC Palliative Care.

CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide

J. Panse, T. Luetkens, D. Atanackovic, 2020, Nature Communications.

Multiple myeloma and family history of lymphohaematopoietic cancers: Results from the International Multiple Myeloma Consortium

N. Camp, J. Spinelli, S. Sanjosé, 2016, British journal of haematology.

ACUTE PSYCHOLOGICAL STRESS SIMULTANEOUSLY ALTERS HORMONE LEVELS, RECRUITMENT OF LYMPHOCYTE SUBSETS, AND PRODUCTION OF REACTIVE OXYGEN SPECIES

D. Atanackovic, H. Deter, M. Brunner‐Weinzierl, 2002, Immunological investigations.

Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD)

T. Luetkens, D. Atanackovic, K. Dunleavy, 2023, Human vaccines & immunotherapeutics.

Genome-wide association study identifies variants at 16 p 13 associated with survival in multiple myeloma patients

Jennifer L. Caswell-Jin, E. Ziv, N. Camp, 2015 .

Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma

J. Miguel, C. Bokemeyer, N. Kröger, 2008, Leukemia.

Anti-SARS-CoV-2 Immune Responses in Patients Receiving an Allogeneic Stem Cell or Organ Transplant

T. Luetkens, D. Atanackovic, J. Baddley, 2021, Vaccines.

9021 Preliminary results of MAGE-A3 expression and baseline demographic data from MAGRIT, a large phase III trial of MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic) in adjuvant NSCLC

D. Atanackovic, J. Strausz, Keunchil Park, 2009 .

Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma

T. Luetkens, N. Kröger, D. Atanackovic, 2014, Leukemia.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.

C. Hofmeister, S. Singhal, Rashmi Kumar, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM).

M. Dimopoulos, R. Vij, T. Zimmerman, 2016 .

Systematic single amino acid affinity tuning of CD229 CAR T cells retains efficacy against multiple myeloma and eliminates on-target off-tumor toxicity

T. Luetkens, D. Atanackovic, Carol S. Lim, 2023, Science Translational Medicine.

Immune-mediated facial nerve paralysis in a myeloma patient post B-cell maturation antigen-targeted chimeric antigen receptor T cells

T. Luetkens, D. Atanackovic, A. Rapoport, 2023, Haematologica.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

C. Hofmeister, A. Krishnan, S. Singhal, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response by 18F-FDG PET/CT Imaging Following CAR-T Therapy.

D. Atanackovic, A. Rapoport, Wengen Chen, 2021, Clinical lymphoma, myeloma & leukemia.

Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma.

M. Daly, N. Camp, Haiyuan Yu, 2018, Cancer research.

CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation

C. Bokemeyer, J. Panse, T. Luetkens, 2008, Haematologica.

Pooled study of occupational exposure to aromatic hydrocarbon solvents and risk of multiple myeloma

N. Camp, J. Spinelli, S. de Sanjosé, 2018, Occupational and Environmental Medicine.

Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients

N. Kröger, D. Atanackovic, M. Kropff, 2013, Bone Marrow Transplantation.

Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma.

N. Kröger, D. Atanackovic, A. Zander, 2009, Experimental hematology.

Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma

D. Atanackovic, W. Chng, T. Fukao, 2023, Cancer medicine.

A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma

M. Dimopoulos, R. Vij, T. Zimmerman, 2015 .